News & Updates

New drug applications approved by US FDA as of 16-31 May 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Individuals with refractory chronic cough (RCC) may find relief in BLU-5937, a selective P2X3 antagonist under development which showed favourable efficacy in reducing cough frequency in the phase IIb SOOTHE trial.

Though relatively rare, medication-related osteonecrosis of the jaw (MRONJ) can nevertheless occur after denosumab treatment, even in the absence of invasive dental treatment, reports a recent study.

Use of a fixed-dose combination therapy or a polypill effectively lowers cardiovascular risk factors but falls short of producing significant reductions in mortality, according to a systematic review and meta-analysis.

In patients on long-term hydroxychloroquine (HCQ) therapy, rapid macular thinning appears to alert a potential retinal damage related to HCQ treatment, a study has found.

Inappropriate prescription practices and polypharmacy remain a burden in patients treated with immune checkpoint inhibitors (ICIs), a study has found.

All urate-lowering therapies work to reduce uric acid concentrations in patients with chronic kidney disease (CKD), although it is unclear whether this benefit extends to those with renal disease, according to the results of a meta-analysis.